Cencora

COR · NYSE

$343.27+$3.27 (+0.96%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $340.00

COR analyst rating

BuyConsensus of 16 analysts over the last 12 months. 81% rate it a buy.

Strong buy0
Buy13
Hold3
Underperform0
Sell0

12-month price target · 15 analysts

Average $373.21 (+8.7% upside)

Low: $333.30
Now: $343.27
High: $451.50

Upgrades and downgrades

The latest rating actions, newest first

COR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Argus Research	Oct 20, 2026	Maintains	Buy	$340.00 → $380.00	66%
UBS	Oct 16, 2026	Maintains	Buy	$430.00 → $400.00	70%
Leerink Partners	Oct 7, 2026	Maintains	Outperform	$380.00 → $388.00	61%
RBC Capital	Sep 8, 2026	Maintains	Sector Perform	$330.00	67%
RBC Capital	Aug 19, 2026	Initiates	Sector Perform	$330.00	67%
Wells Fargo	Aug 11, 2026	Maintains	Overweight	$331.00 → $395.00	59%
Morgan Stanley	Aug 7, 2026	Maintains	Overweight	$342.00 → $346.00	73%
JP Morgan	Aug 7, 2026	Maintains	Overweight	$382.00 → $390.00	54%
UBS	Aug 6, 2026	Maintains	Buy	$412.00 → $430.00	70%
Evercore ISI Group	Aug 6, 2026	Maintains	Outperform	$330.00 → $350.00	67%

The case for and against

Updated Oct 15, 2026

Bull case

Cencora is positioned favorably because its leading specialty distribution franchise and vertically integrated platform across patient support, data analytics, and MSO services should sustain mid-single-digit revenue growth even as the drug market slows. Its scale in an industry where it and two peers control over 90% of U.S. wholesale share, plus expanded international reach from Alliance Healthcare, reinforces resilient demand across retail, hospital, specialty, and animal health channels. The bullish case is further supported by biosimilar adoption, which can offset IRA-related pricing pressure and add about $185M in operating income by 2028 through higher-margin mix, while robust specialty volume could drive modest margin expansion.

Bear case

Cencora is facing a negative outlook because its core pharmaceutical distribution economics are under pressure from IRA and MFN pricing reforms, which could reduce margins and slow Pharma segment growth to the mid-single digits as roughly $28B of Medicare drug spend becomes exposed to 40%-60% price cuts. Its competitive position is also vulnerable to customer concentration, contract renewal risk, and intensified rivalry from McKesson and Cardinal Health, while accelerated manufacturer direct-to-consumer distribution could further erode traditional wholesaler volumes. In animal health, FTC scrutiny of the MWI-Covetrus merger adds antitrust uncertainty, and the combined entity could control an estimated 67%-75% of the US veterinary distribution market, increasing execution and regulatory risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.